The first new TB medicines in over 40 years—bedaquiline and delamanid—were recently released onto the market for the treatment of multidrug-resistant tuberculosis (MDR-TB). Since then, these medicines have been used for the treatment of MDR-TB patients as well as TB patients who have experienced life-altering side effects or developed intolerance or resistance to some second-line TB drugs.
On this website, you will find general information about bedaquiline (Sirturo™) and delamanid (Deltyba™) from globally recognized bodies such as the World Health Organization. There are also guidance documents about active surveillance of new TB medicines, training materials for clinicians who will be treating MDR-TB patients using the new medicines, clinical management resources including treatment algorithms, information about treating special patient populations pediatric patients, TB/HIV co-infected patients, and pregnant and breastfeeding women among others. There are also sample informed consent forms and forms for reporting on serious adverse events for use.
If you are unsure where to begin with the adoption and implementation activities for the new drugs, review the Getting Started guide which is a generic guidance on how to implement the new drug(s) in country. This guide will highlight the steps to take in introducing and adopting new TB medicines including stakeholder coordination, planning activities for medicine use, accessing the USAID Bedaquiline Donation Program and much more. It is designed to be a starting point for countries that plan to use new TB medicines; however, it is not all encompassing. For more comprehensive technical assistance on any areas of new TB medicine adoption, contact us via email at newTBdruginfo@msh.org.
- Bedaquiline treatment reaches patients in Uganda, Swaziland, Philippines, and Georgia
The Systems for Improved Access to Pharmaceuticals and Services (SIAPS) Program works with countries to adopt new medicines and regimens, ...
- New TB Medicines & Regimens eCourse
- On the Market: Interviews on Bedaquiline Use
In April 2015, USAID and Janssen Therapeutics officially launched the bedaquiline ...
Georgia: First Recipient of Free Bedaquiline
From left to right: The USAID Acting Mission Director in Georgia, Thomas R. Morris, Executive director of the National Center for TB and lung diseases of Georgia, Zaza Avaliani; United States Ambassador to Georgia, Ian C. Kelly